Skye Bioscience Faces Investor Lawsuit Following Clinical Trial Setback

Shares of biotechnology firm Skye Bioscience are experiencing significant turmoil. The company is now confronting a class action lawsuit filed by investors, compounding the pressure from disappointing clinical trial results for its lead drug candidate announced last fall. The legal action alleges the company made misleading statements and inflated expectations.

The legal firm Faruqi & Faruqi, LLP has initiated a nationwide class action investigation against Skye Bioscience and formally filed suit. The complaint centers on accusations that the company issued materially misleading business statements and failed to disclose that its drug candidate, Nimacimab, was less effective than investors had been led to believe. This alleged misrepresentation is said to have overstated Read more...